USC Norris Comprehensive Cancer Center | Strategic Alliance Partners

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, believes this is an exciting time in the field of gastrointestinal cancers, as more tools become available to select the most effective treatment for each patient.

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses targeting HER2 in breast cancer.

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Barbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the ATLAS trial that compared 5 years of adjuvant tamoxifen to 10 in patients with estrogen receptor-positive early breast cancer.

In interviews with OncologyLive, Debu Tripathy, MD, and William Gradishar, MD, discussed their views of the most important abstracts presented during the San Antonio Breast Cancer Symposium.

Heinz-Josef Lenz, MD, has focused his research on a range of scientific and translational questions, including the regulation of gene expression in drug resistance and targeted therapies.

The pace of discovery in breast cancer research has been brisk in the past year, leading not only to the approval of several new therapies but also to clinical trial results with the potential to change practice.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined GRN1005 in patients with brain metastases from breast cancer.